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Introduction
Somatostatin (SST) is a well known neurohormone
peptide that occurs in two molecular forms with 14 or
28 aminopeptide residues. It is widely distributed in
the central and peripheral nervous system, the pituitary
gland and other tissues such as the pancreas, adrenals,
intestine, kidneys, prostate, placenta and the immune
system cells. SST exerts a number of different biolog-
ical effects, predominantly of inhibitory nature (for
review see: [1]). One of the most encouraging aspects
of somatostatin effects and, particularly in the context
of tumor diseases therapy, is its antiproliferative action
[2]. SST as well as its synthetic analogs acts via spe-
cific receptors which are present on the surface of the
target cells. Five subtypes of the SST receptor have
been identified so far, i.e. SSTR 1-5 with two variants
(2A and 2B) of the type 2 receptor [3,4]. These belong
to a group of 7 transmembrane domains linked with
the G protein [5] and are encoded by 5 genes which are
present on separate chromosomes [6,7]. In the cell the
SST receptors can be found on the cell membrane or in
the cytoplasm region. Particular SSTR subtypes can
occur alone or be grouped together in the same cell.
SSTR are present both in normal and in tumor tissues
which enables their response to applied SST analogs
(for review see: [8]). If the investigated tumor shows
the expression of more than one subtype of the SST
receptor it cannot be predicted via which of these the
SST analog action will be exerted. Expression of the
receptors in a given tumor enables to apply a ligand
that would react specifically with the only detected
receptor or a SST multiligand which would react
specifically with several receptors. The SST analogs -
octreotide and lanreotide, which are widely applied at
present, act mainly via 2 and 5 receptor subtypes and
thus, are not always effective in the therapy of tumors
expressing other receptor subtypes . The use of the
SST multiligands that express the affinity to majority
of SSTR subtypes and would therefore act more effec-
tively in a given tumor has been postulated. Different
techniques are being currently applied to detect SST
receptors in human tumors. Octreoscan, receptor
scintigraphy using indium labeled SST analogs - 111
In-pentetreotide (111 In-DTPA) octreotide [9] or tech-
netium labeled (99mTc-EDDA/HYNIC-Tate) octreo-
tate [10] have been proved most useful in vivo. These
methods allow to determine in vivo the tumor localiza-
tion and size with good precision, however their effec-
tiveness depends on the presence of subtype 2 SSTR in
the tumor. Moreover in the detection of adrenal
tumors, receptor scintigraphy is difficult because of
the strong signals from kidneys. Nevertheless, the
immunohistochemical (IHC) technique performed on
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paraffin embedded tissue specimens obtained from
surgically removed tumors seems the best ex vivo in
vitro method in detecting subcellular distribution of
SST receptors. The observations of negative results
obtained with octreoscan in pheochromocytoma or
neuroendocrine tumors (NET) where the presence of
SST receptors in the investigated tumors was demon-
strated using the immunohistochemical method solely
have been published [11,12]. As a consequence,
patients with negative results of receptor scintigraphy
and with positive immunohistochemical reaction for
SST receptors lost their chance of treatment with SST
analogs. On the other hand, in approximately 15% of
patients with positive octreoscan there were no SST
receptors found in the tumor, which excludes any suc-
cessful treatment with SST analogs. Currently applied
methods of molecular biology (PCR, RT-PCR,
Western-blotting) are useful exclusively in detecting
receptor mRNA, while giving no insight into receptor
localization. Apart from that, these methods are often
burdened with false positive results.
Despite the fact that the adrenal gland has long
been known as the target organ for SST and SST
receptors have been found there in physiological con-
ditions [13,14] data concerning the occurrence of
SSTR in human adrenal gland tumors are still scarce
and often conflicting [15-18]. Somatostatin analogs
are not routinely used in treatment of adrenal tumors
so far. The aim of our study was to assess systemati-
cally the presence of all the 5 subtypes of SSTR
(including 2A and 2B SSTR isoforms) in surgically
treated human adrenal tumors.
Material and methods
In this study 21 surgically treated adrenal gland tumors were
assessed. The material was obtained from 15 women and 6 men
aged between 42 and 67 years (mean age 55 years). Histological
examination of the operated tumors revealed adrenal adenoma in
11 cases (9 clinically nonfunctioning tumors, 1 case of  Conn's dis-
ease and 1 case of Cushing's syndrome), adrenal cortex hyperpla-
sia associated with ectopic release of ACTH in 1 case, adrenal cor-
tex cancer in 2 cases and pheochromocytoma in 7 cases.
Bouin's fixed, dehydrated and paraffin embedded 8-μm sections
were immunostained using commercially available rabbit poly-
clonal antisera raised against carboxyl-terminal fragments of spe-
cific human somatostatin receptor subtypes (GRAMSCH Labora-
tories, Schwabhausen, Germany): SSTR 1 (named SS-840 anti-
body, corresponding to amino acid sequence 377-391 of the recep-
tor's peptide chain), SSTR 2A (SS-800, specific for 355-369
sequence), SSTR 2B (SS-860, specific for 342-356 sequence),
SSTR 3 (SS-850, specific for 381-395 sequence) SSTR 4 (SS-880,
specific for 374-388 sequence) and SSTR 5 (SS-890, specific for
350-364 sequence). The immunohistochemical procedures were
performed as previously described [19]. The working dilution of
antibodies was 1:1000 (diluted in 0.05 M TRIS buffer, pH=7.6
containing 2% goat serum). Following overnight incubation in 4°C
in humidified chamber with primary antibodies, the cells were
treated with anti-rabbit IgG biotinylated goat antibody (1:800,
DAKO, Denmark) and streptavidin complex (Strept ABC/HRP,
DAKO, Denmark). The immunoreaction was visualized with 3,3'-
diaminobenzidine (DAB, DAKO, Denmark) solution. For negative
controls the primary antibody was replaced by normal goat serum.
The immunoreactive intensity for specific receptor proteins was
assessed semiquantitatively using a descriptive method as follows:
strong staining (+++), moderate staining (++), weak staining (+)
and pale staining (+/-). Subcellular distribution pattern of SSTR
subtypes - membranous or cytoplasmic was also determined. 
Results
Adrenal adenomas
The samples obtained from 11 cases of adrenal adeno-
ma were characterized by markedly differentiated
results. Multiple SSTR subtypes were found to coexist
in each of them. Most of the specimens showed mixed
distribution pattern of the receptors - cytoplasmic and
membranous with one of them being predominant in
the particular cases (Table 1).
Strong and moderate, both cytoplasmic and mambra-
nous immunostatining of SSTR 1 was demostrated in 7
(63,6%) cases (Fig.1). Strong staining was detected in
the cell membranes in 2 specimens and moderate stain-
ing in the cytoplasm was found in another 2 specimens.
In case of SSTR 2A strong or moderate immunostaining
with exclusively cytoplasmic distribution was shown in
3 (27.3%) slides, whereas strong or moderate staining
with mixed, cytoplasmic and membranous distribution
was found in 4 slides (Fig. 2) and moderate or weak
membranous staining - in 3 cases. Mixed weak staining
was found in 1 case. Staining for SSTR 2B was restrict-
ed to the cytoplasm and was characterized by strong or
moderate intensity occurred in 4 (36.4%) specimens;
mixed distribution - cytoplasmic and membranous
occurred in 3 cases and exclusively membranous local-
ization was seen in 2 cases. In the 2 remaining samples
weak cytoplasmic or weak mixed cytoplasmic and mem-
branous staining was found. 
Staining for SSTR 3 was also characterized by
mixed distribution and various intensity. Strong and
moderate staining which was distributed both in the
cytoplasm and the membranes was shown in 6 speci-
mens. Strong or moderate staining in the cell cyto-
plasm was detected in 2 cases, strong or moderate
staining in the cell membrane - in 2 cases and weak
staining with mixed localization - in 1 case. 
Moderate immunostaining for subtype 4 receptor
was found in 2 (18.2%) cases of adrenal adenoma the
intensity was weak or pale in 4 (36.4%) cases, never-
theless in each of the 6 slides SSTR 4 showed cyto-
plasmic localization. No presence of SSTR 4 was
found in the remaining 5 (45.5%) cases. In 1 slide we
found quite a strong staining in the cells of the adrenal
medulla which were present in the specimen.
Similarly to SSTR 1, 2A, 2B and 3, SSTR 5 was
characterized by mixed distribution - cytoplasmic and
membranous. Strong staining in the cytoplasm was
present in 4 (36.4%) cases, whereas in 7 (63.6%)
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specimens it was distributed in both the cytoplasm
and the membranes. 
Adrenal cortex carcinomas
Except for SSTR 4, all subtypes of SSTR were found
to coexist in 2 cases of adrenal cortex carcinoma
(Table 2). SSTR 1, 2A, 2B, 3, 5 were present in 1 case
and were distributed both in the cytoplasm and the cell
membrane with predominantly moderate and weak
intensity of staining (Fig. 3,4,5). In the latter case
immunostaining was only seen in the cytoplasm.
Receptor subtypes SSTR 1-5, excluding SSTR 4
were detected in the specimen obtained from a patient
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Figs. 1-2. Adrenal cortex adenoma.
Fig. 1. Nr 2444, SSTR 1 (magnifi-
cation ×200). Fig. 2. Nr 2444,
SSTR 2A (magnification ×200).
Figs. 3-5. Adrenal cortex carcinoma.
Fig. 3. Nr 1846, SSTR 2A (magnifi-
cation ×200). Fig. 4. Nr 1846, SSTR
2B (magnification ×200). Fig. 5. Nr
1846, SSTR 3 (magnification ×400).
Figs. 6-8. Pheochromocytoma. 
Fig. 6. Nr 1926, SSTR 2A (magnifi-
cation ×200). Fig. 7. Nr 1926, SSTR
2B, (magnification ×200). Fig. 8. Nr
1926, SSTR 3, (magnification
×200).
with adrenal cortex hyperplasia due to ectopic release
of ACTH by thymoma (nr 2350) and were distributed
both in the cell membrane and the cytoplasm (Table 3).
Strong staining was found for SSTR 1 and moderate -
for SSTR 5.
Pheochromocytomas
In 6 (85%) out of 7 examined specimens SSTR sub-
types 1, 2A, 2B, 3 and 5 coexisted and the staining was
defined as strong or moderate (Table 4). Strong
immunostaining for SSTR 1 was detected in 3 (42.8%)
cases. Strong staining for SSTR 2A was found in 4
(57.14%) cases (Fig. 6), for SSTR 2B - in 1 (14.28%)
case, SSTR 3 - in 3 (42.8%) cases (Fig. 8) and for
SSTR 5 - in 4 (57.14%) specimens. No presence of
SSTR 4 was found in 6 (85.71%) cases. In 1 case this
subtype of receptor was demonstrated in moderate
staining (14.28%). Weak or pale staining for receptors
SSTR 1, 2A, 2B, 3 and 5 was shown in only 1 speci-
men (nr 2132). In all the examined specimens SST
receptors were localized in the area of the cell cyto-
plasm which showed a positive staining (Fig. 7). Local
strong or moderate staining in the endothelium was
demonstrated in one specimen.
Discussion
Results of the present study demonstrate that adrenal
tumors which derive both from the cortex and the
medulla of the organ show strong expression of
somatostatin receptors, which is consistent with earli-
er reports. All the examined adrenal cortex adenomas
were characterized by positive staining for SSTR 1,
SSTR 2A, SSTR 2B, SSTR 3 and SSTR 5 of different
intensity. Staining for SSTR 4 which was found nega-
tive in 45% or pale (36.4%) was an exception. Due to
the paucity of the material it is impossible to answer
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Table 1. Somatostatin receptor subtypes in adrenal cortex adenomas.
Abbreviations: mem - membranous localization; cytopl - cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+) and
pale staining (+/-).
the question whether there is any difference in SSTR
expression between hormonally active and nonfunc-
tioning adenomas. Unger et al. [17] examined 7 non-
functioning adenomas and found positive immunos-
taining for SSTR 1, 2A and 3 in 2/3 of cases. Almost
all nonfunctioning adenomas showed the expression of
subtype SSTR 5 with positive staining in 30-60% of
cells. Almost all cases of Cushing's syndrome and
Conn's syndrome that were studied by these authors
were positive for SSTR subtypes 1-5 with positive
staining in 30% of cells. All the SSTR subtypes, except
for SSTR 4 were also found in both cases of adrenal
carcinoma in the present study. In the experience of
Unger et al. 50% of adrenal carcinomas (4 cases)
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Abbreviations: mem - membranous localization; cytopl - cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+) and
pale staining (+/-).
Abbreviations: mem - membranous localization; cytopl - cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+) and
pale staining (+/-).
Abbreviations: mem - membranous localization; cytopl - cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+) and
pale staining (+/-).
Table 2. Somatostatin receptor subtypes in adrenal cortex carcinomas.
Table 3. Somatostatin receptor subtypes in adrenal cortex hyperplasia.
Table 4. Somatostatin receptor subtypes in pheochromocytomas.
showed the expression of SSTR 2A and SSTR 3 with
positive immunostaining in 30-100% of cells. Interest-
ingly, SSTR1 subtype did not occur in any of them.
Similarly, we demonstrated positive staining for all
SSTR subtypes but SSTR 4, which occurred in moder-
ate intensity in only 1 (14.3%) case. Receptor 2A and
5 subtypes were expressed in 57.14% of cases and
SSTR 1 and 3 in equal amounts - 42.8%. In the study
by Pasquali et al. [20] expression of SSTR 3 was
detected in 90% of studied pheochromocytomas while
that of SSTR 2A in only 25%; the remaining SST
receptors were expressed in still smaller percentage of
cases. Using immunohistochemical methods, Mund-
schenk et al. [13] found the presence of SSTR 3 in
90%, SSTR 2A - in 25%, SSTR 4 - in 10%, SSTR 5 -
in 15% and SSTR 1 - in 8% of studied pheochromocy-
tomas. Unger et al. [17] demonstrated the expression
of SSTR 1, 2A and 5 in 1/3 of the studied pheochro-
mocytomas with 30% positive staining cells whereas
SSTR 3 occurred in all of the cases and the percentage
of cells with positive staining was 60%.
Diversity of reported results has also been reflected
in the studies on the expression of SST receptors that
have been conducted using molecular biology tech-
niques, particularly the PCR. The mRNA for mainly
SSTR 5 was found in a series of human corticotropic
adenomas [21]. No presence of SSTR 5 in any of 10
studied pheochromocytomas was shown by this
method and SSTR 1 was detected in almost all cases
[18]. Expression of all the 5 subtypes was equally dis-
tributed in aldosterone producing adenomas (Conn's
syndrome). Using autoradiography, Epelbaum et al.
[15] earlier found the presence of mRNA of all the five
subtypes of SSTR in pheochromocytomas and they
concluded that SSTR 2 and SSTR 4 mRNA occurred
most frequently in these tumors, whereas SSTR 5 was
identified in only 6% of cases.
Although majority of immunopositive cells were
characterized by homogenous distribution in the area
of engaged tissue, marked concentration of intensely
immunoreactive cells was found in 2 cases of adrenal
adenomas (1847, 2270) and 1 case of pheochromocy-
toma (2132) that have been analyzed in the present
study, nevertheless general staining for a given recep-
tor remained weak like, for example in the cells of the
adrenal medulla or in the cytoplasm region. This
observation indicates differences in the receptor densi-
ty in individual cases. Cellular localization of investi-
gated receptors should also be taken into considera-
tion. SSTR subtypes that have been assessed in this
study were located both in the cell cytoplasm and in
the cell membrane. Other authors [16,22,23] also
report cytoplasmic localization of SSTR 1, 3, 4, 5, the
membranous distribution of SSTR 2A and expression
of SSTR 3 both in the cell membrane and in the cyto-
plasm. Hofland et al. (24) observed expression of
SSTR 2 in the cell membrane and Reubi et al. [25]
using another specific antibody (R2-88) showed both
cytoplsmic and membranous expression of SSTR 2A
in pheochromocytomas. This phenomenon could be
explained by the so called receptor internalization by a
specific ligand, which is essential in the in vivo ligand-
receptor interaction. Thus, localization of the receptor
results from its subcellular "processing" due to syn-
thetic activity, mechanisms of binding receptor to a
ligand or receptor desensitization. Reubi et al. [25]
consider subcellular distribution of SSTR 2A as the
effect of autocrine activity of somatostatin that is pro-
duced by the tumor (e.g. pheochromocytoma), which
can result in spontaneous internalization of the recep-
tor and in avoiding its binding to the ligand. However,
it has not been elucidated thus far, how subcellular
localization of receptors which are detected by
immunohistochemistry affects the expected biological
effects. Results of the present study confirm high effi-
cacy of immunohistochemical investigation of SSTR
expression using antibodies specific for a given recep-
tor subtype - a method considered supplementary or
even equally effective as methods of  molecular biolo-
gy or diagnostic imaging. Usefulness of this method
can even be considered superior to those due to lower
costs of reagents (molecular biology), shorter time of
providing results and lack of using radioactive
reagents (receptor scintigraphy). Besides, receptor
mRNA detected by molecular biology techniques
(PCR, RT-PCR) does not seem a reliable proof of its
presence. In fact, it is genetic material detected rather
than the receptor protein being a real target for somato-
statin and its analogs. Despite and partly due to their
marked sensitivity, methods of molecular biology
often provide results that are falsely positive and are
associated with expression of somatostatin receptors in
structures such as vascular endothelium or tumor infil-
trating immunocytes.
Conclusion
Results of the present study demonstrate that somato-
statin receptors are expressed in adrenal tumors in a
varied manner which is specific in each case. It pro-
vides different diagnostic and therapeutic possibilities.
Our data provide the rationale to therapeutic trials of
somatostatin analogs in adrenal tumors. The diversity
and coexistence of several somatostatin receptor sub-
types in one tumor unables unequivocal prediction
which receptor subtype would react with somatostatin
analog. Therefore, apart from applying octreotide and
lanreotide, newly synthesized multiligand analogs
such as SOM 230 or KE 108 should be considered also
as therapeutic agents in adrenal tumors. The decision
as to therapeutic strategy choice should be taken indi-
vidually in each case of adrenal tumor.
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